Validation of computational approaches for antiretroviral dose optimization

Siccardi, M ORCID: 0000-0002-3539-7867, Dickinson, L ORCID: 0000-0001-5557-9396 and Owen, A ORCID: 0000-0002-9819-7651
(2016) Validation of computational approaches for antiretroviral dose optimization. Antimicrobial Agents and Chemotherapy, 60 (6). pp. 3838-3839.

[img] Text
Antimicrob. Agents Chemother.-2016-Siccardi-3838-9.pdf - Submitted version

Download (333kB)


Strategies for reducing antiretroviral doses and drug costs can support global access, and numerous options are being investigated. Efavirenz pharmacokinetic simulation data generated with a bottom-up physiologically based model were successfully compared with data obtained from the ENCORE (Exercise and Nutritional Interventions for Cardiovascular Health) I clinical trial (efavirenz at 400 mg once per day versus 600 mg once per day). These findings represent a pivotal paradigm for the prediction of pharmacokinetics resulting from dose reductions. Validated computational models constitute a valuable resource for optimizing therapeutic options and predicting complex clinical scenarios.

Item Type: Article
Uncontrolled Keywords: Humans, HIV, HIV Infections, Alkynes, Cyclopropanes, Benzoxazines, Anti-HIV Agents, Microbial Sensitivity Tests, Drug Administration Schedule, Area Under Curve, Models, Statistical, Gene Expression, Clinical Trials as Topic, Drug Dosage Calculations, Mutation Rate, Cytochrome P-450 CYP2B6
Depositing User: Symplectic Admin
Date Deposited: 06 Apr 2017 12:14
Last Modified: 19 Jan 2023 07:26
DOI: 10.1128/AAC.00094-16
Related URLs: